1. Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib.
- Author
-
Haas NA, Nossal R, Schneider CH, Lewin MA, Ocker V, Holder M, and Uhlemann F
- Subjects
- Bartter Syndrome physiopathology, Humans, Infant, Newborn, Sulfones, Bartter Syndrome drug therapy, Cyclooxygenase Inhibitors therapeutic use, Lactones therapeutic use
- Abstract
Objective: To describe the successful treatment of an unusual case of severe neonatal Bartter's syndrome refractory to treatment with indomethacin., Design: Case report, clinical., Setting: Tertiary care intensive care unit., Patients: A patient with neonatal hyperprostaglandin-E syndrome and excessive requirements of intravenous (via central venous catheter) water and salt supplementation, failure to thrive, vomiting, and massive growth retardation, despite adequate treatment with indomethacin., Main Result: Four weeks after induction of the new cyclooxygenase-2 inhibitor rofecoxib, the patient was well, on full enteral feeds, thriving, and had gained 600 g in weight. A lower supplementary potassium, magnesium, and sodium intake was required. Reinstitution of indomethacin therapy resulted in severe deterioration, despite high indomethacin doses; symptoms improved again after rofecoxib administration. No side effects have been seen thus far., Conclusion: This report shows that in selected patients with a severe form of neonatal Bartter's syndrome, the new cyclooxygenase-2 inhibitor rofecoxib may control the clinical symptoms of hyperprostaglandin-E syndrome after ineffective indomethacin therapy.
- Published
- 2003
- Full Text
- View/download PDF